Drug Profile

Home  Drug Profile  Safety Watch  Library  Contact Us

Pivotal Safety Information

MedWatch in Perspective

Our Adverse Event Profile provides a crisp summary and software tools to explore one of the most important sources of information about the toxic properties of prescription drugs. It is based on the MedWatch reports submitted to the FDA.

While the raw data can be obtained through the Freedom of Information Act, interpreting the thousands of reports and avoiding the technical pitfalls requires a great deal of time and expertise.

The profile is engineered not only to display key trends and important facts quickly, but also to provide the tools to explore items of interest in depth.

Details and examples from our the complete report are shown in the Tour the Contents section.

A sample graphic from the profile.

Report Viewer

Select, view and print cases of interest with the report viewer. Complete report database is also included.

 

Order Profile

By Phone: 202-530-2348

By Email: Just Click Here

Normal delivery time is two weeks from receipt of payment. Expedited available.

 

Tour the Contents

Test the innovative features of our report

Time Trends

See how plotting reports over time reveals important perspectives on the adverse events for the target drug.

Report Totals and Type

Sometimes the key insight comes from looking at the messenger (types of reports) as well as the message (the adverse event).

Patient Profile

Almost always it is important to understand what kind of patients were injured by the target drug. In the example here, the profile was surprising.

Deaths and Other Outcomes

The number of people and the severity of their injuries is almost always a key issue. The role of the drug can also be an important issue.

Other Drugs Taken

Life would be simpler if people only took one drug at a time. In reality, understanding the role of other drugs that may interact or be involved is essential.

 

Kinds of Reactions

Was the problem liver failure, a stroke or violent behavior? Two displays put this central issue in perspective.